Cell line · CVCL_D603
Papers93
12 more articles give this line's RRID in its Methods without naming the line nearby, so they are not listed.
1 to 20 of 93
Download this page as JSON| Paper | Journal | Year | How we know | Retracted | Source |
|---|---|---|---|---|---|
| Canonical Antibodies Adopt Distinct Binding Modes to Recognize Viral Glycan Shields. | Adv Sci (Weinh) | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Development and characterization of a long-acting allosteric growth hormone receptor antagonist for acromegaly. | Endocrinology | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Genotoxic antibody-drug conjugates combined with BCL-XL inhibitors enhance therapeutic efficacy in metastatic castration-resistant prostate cancer. | J Clin Invest | 2026 | Its Methods give the RRID and name the line | PubMed | |
| A Wnt-induced conformational phospho-switch in DVL3 controls association with Frizzled receptors and Wnt/β-catenin signaling. | Sci Adv | 2026 | Its Methods give the RRID and name the line | PubMed | |
| A Precision-Engineered DC-Targeting mRNA-LNP Neoantigen Vaccine Elicits Stronger T Cell Responses and Exhibits Superior Tumor Control. | Vaccines (Basel) | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Identification and characterization of bone marrow plasma cells producing IFN-γ-neutralizing autoantibodies in adult-onset immunodeficiency. | Cell Rep Med | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Antagonist nanobodies prevent protease inhibition by CD109. | J Biol Chem | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Function-driven design of a surrogate interleukin-2 receptor ligand. | FEBS Lett | 2026 | Its Methods give the RRID and name the line | PubMed | |
| IgG-Bridging-Seeded Synergistic Aggregation of SARS-CoV-2 Spikes Underlies Potent Neutralization by a Low-Affinity Antibody. | Adv Sci (Weinh) | 2026 | Its Methods give the RRID and name the line | PubMed | |
| The fc fragment of IgMs binds C1q to activate the first step of the classical complement pathway, while inhibiting complement-dependent cytotoxicity. | FEBS J | 2026 | Its Methods give the RRID and name the line | PubMed | |
| CLEC18A interacts with sulfated glycosaminoglycans and controls clear cell renal cell carcinoma progression. | FEBS J | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Long lasting complement neutralisation by RAY121, an engineered anti-C1s antibody with C1q displacement function. | EBioMedicine | 2025 | Its Methods give the RRID and name the line | PubMed | |
| SLC25A45 is required for mitochondrial uptake of methylated amino acids and de novo carnitine biosynthesis. | Mol Cell | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Genotoxic antibody-drug conjugates combined with Bcl-xL inhibitors enhance therapeutic efficacy in metastatic castration-resistant prostate cancer. | bioRxiv | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Development of a cyst-targeted therapy for polycystic kidney disease using an antagonistic dimeric IgA monoclonal antibody against cMET. | Cell Rep Med | 2025 | Its Methods give the RRID and name the line | PubMed | |
| CD4 T cell counts are inversely correlated with anti-gp120 cluster A antibodies in antiretroviral therapy-treated PLWH. | EBioMedicine | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Structural and functional insights into the evolution of SARS-CoV-2 KP.3.1.1 spike protein. | Cell Rep | 2025 | Its Methods give the RRID and name the line | PubMed | |
| The co-receptor Tetraspanin12 directly captures Norrin to promote ligand-specific β-catenin signaling. | Elife | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Glu592 of the axon guidance receptor ROBO3 mediates a pH-dependent interaction with NELL2 ligand. | FEBS Lett | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Tumor Integrin-Targeted Glucose Oxidase Enzyme Promotes ROS-Mediated Cell Death that Combines with Interferon Alpha Therapy for Tumor Control. | Mol Cancer Ther | 2025 | Its Methods give the RRID and name the line | PubMed |
cell-lines-2026-11-14-0.1.0
Sources 4
- CellosaurusCC BY 4.0, with credit to Cellosaurus (SIB)
- PubMed Central's articlesTitles shown only for CC0, CC BY and public domain articles
- NLM's PMC Article DatasetsCourtesy of NLM, which does not endorse this database
- PubMedNLM's terms
Each source's terms
- CellosaurusCC BY 4.0. Cellosaurus's README: "we have chosen to apply the Creative Commons Attribution 4.0 International (CC BY 4.0) license to Cellosaurus (https://creativecommons.org/licenses/by/4.0/). This means that you are free to copy and redistribute Cellosaurus in any medium or format. You can remix, transform, and build upon Cellosaurus for any purpose, even commercially. You must give appropriate credit, provide a link to the license, and indicate if changes were made." Copyright (c) CALIPHO group, SIB Swiss Institute of Bioinformatics. Read on 14 Nov 2026 at https://ftp.expasy.org/databases/cellosaurus/README
- PubMed Central's articlesEach article's own license. Its words show only under CC0, CC BY or public domain
- NLM's PMC Article DatasetsNLM's PMC Article Datasets on AWS, https://registry.opendata.aws/ncbi-pmc. Its terms: users "acknowledge NLM as the source of the data in a clear and conspicuous manner", do not use the PubMed Central wordmark or the PMC logo, do not "indicate or imply that NLM/NIH/HHS has endorsed" a product, and "only distribute data that are licensed for redistribution". Each article keeps its own license: https://pmc.ncbi.nlm.nih.gov/about/copyright/
- PubMedNLM's terms
Cellosaurus, SIB Swiss Institute of Bioinformatics, https://www.cellosaurus.org, CC BY 4.0. Its problem notes are given in its own words.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/cell-lines/v1/CVCL_D603/papers